Review Article
TAS-102 Monotherapy and Combination Therapy with Bevacizumab for Metastatic Colorectal Cancer
Table 5
Meta-analysis results for the occurrence of adverse events in controlled experiments.
| | Outcomes | Any grade | | | Intervention | Trials | OR (95% CI) | | | Intervention | Trials | OR (95% CI) | | |
| | Nonhematological | | | | | | | | | | | | Vomiting | TAS-102 | 5 | 2.99 (2.17-4.13) | 16.70% | <0.001 | TAS-102 | 5 | 3.72 (1.21-11.43) | 0% | 0.022 | | TAS-102+B | 1 | 0.53 (0.09-3.03) | | 0.479 | | | | | | | Nausea | TAS-102 | 3 | 3.32 (1.31-4.44) | 0% | <0.001 | TAS-102 | 2 | 1.79 (0.54-5.90) | 0% | 0.338 | | TAS-102+B | 2 | 0.80 (0.36-1.78) | 0% | 0.59 | TAS-102+B | | | | | | Asthenia | TAS-102 | 5 | 1.45 (1.08-121.96) | 55.40% | 0.015 | TAS-102 | 8 | 0.85 (0.58-1.25) | 0% | 0.4 | | TAS-102+B | 2 | 1.43 (0.76-2.66) | 0% | 0.265 | TAS-102+B | 2 | 0.59 (0.11-3.17) | 0% | 0.534 | | Decreased appetite | TAS-102 | 6 | 1.43 (0.90-2.26) | 61.90% | 0.127 | TAS-102 | 7 | 0.88 (0.58-1.32) | 0% | 0.527 | | TAS-102+B | 1 | 0.54 (0.13-2.29) | NA | 0.405 | TAS-102+B | 2 | 0.17 (0.02-1.42) | 0% | 0.1 | | Diarrhea | TAS-102 | 4 | 1.63 (0.79-3.37) | 55.70% | 0.043 | TAS-102 | 3 | 1.30 (0.13-12.59) | 60.60% | 0.82 | | TAS-102+B | 2 | 0.73 (0.10.5.62) | 0% | 0.453 | TAS-102+B | 1 | 0.14 (0.01-3.02) | NA | 0.209 | | Abdominal pain | TAS-102 | 2 | 1.23 (0.86-1.76) | 0% | 0.256 | TAS-102 | 4 | 0.57 (0.30-1.06) | 0% | 0.075 | | Fever | TAS-102 | 3 | 0.42 (0.09-2.02) | 86.60% | 0.277 | TAS-102 | 2 | 3.14 (0.54-18.10) | 0% | 0.201 | | Hematological | | | | | | | | | | | | Neutropenia | TAS-102 | 4 | 28.21 (1.40-568.32) | 96.60% | 0.029 | TAS-102 | 9 | 32.40 (12.88-81.52) | 31.00% | <0.001 | | Anemia | TAS-102+B | 1 | 3.33 (1.10-10.12) | NA | 0.034 | TAS-102+B | 3 | 2.37 (1.17-4.77) | 34.20% | 0.016 | | TAS-102 | 3 | 4.94 (3.11-7.85) | 63.50% | <0.001 | TAS-102 | 8 | 4.38 (2.78-6.89) | 26.70% | <0.001 | | TAS-102+B | 2 | 0.58 (0.20-1.69) | 0% | 0.321 | TAS-102+B | 2 | 0.61 (0.25-1.48) | 0% | 0.272 | | Leukopenia | TAS-102 | 2 | 72.00 (42.51-121.95) | 0% | <0.001 | TAS-102 | 5 | 24.16 (6.12-95.34) | 14.10% | <0.001 | | TAS-102+B | 1 | 1.80 (0.77-4.19) | NA | 0.172 | TAS-102+B | 1 | 1.54 (0.73-3.24) | NA | 0.258 | | Febrile neutropenia | TAS-102 | 2 | 7.83 (0.75-81.26) | 17.70% | 0.085 | TAS-102 | 5 | 7.71 (2.11-28.16) | 0% | 0.002 | | TAS-102+B | 1 | 0.42 (0.08-2.25) | NA | 0.312 | TAS-102+B | 1 | 2.24 (0.20-25.37) | NA | 0.514 | | Thrombocytopenia | TAS-102 | 4 | 2.27 (0.51-10.22) | 93.10% | 0.284 | TAS-102 | 6 | 1.21 (0.38-3.80) | 64.30% | 0.749 | | TAS-102+B | 2 | 2.17 (0.39-11.91) | 41.90% | 0.374 | TAS-102+B | 1 | 0.74 (0.04-12.49) | NA | 0.836 |
|
|
